(19)
(11) EP 4 771 160 A2

(12)

(88) Date of publication A3:
19.06.2025

(43) Date of publication:
08.07.2026 Bulletin 2026/28

(21) Application number: 24860883.8

(22) Date of filing: 27.08.2024
(51) International Patent Classification (IPC): 
C12N 15/54(2006.01)
C12N 15/90(2006.01)
C12N 15/85(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/711; A61K 45/06
(86) International application number:
PCT/US2024/044040
(87) International publication number:
WO 2025/049480 (06.03.2025 Gazette 2025/10)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 31.08.2023 US 202363536013 P

(71) Applicant: Visgenx, Inc.
Rancho Mission Viejo, CA 92694 (US)

(72) Inventors:
  • CHAVEZ, Christopher
    Mission Viejo, California 92694 (US)
  • EMANUELE, Martin
    Mission Viejo, California 92694 (US)

(74) Representative: Zacco Sweden AB 
P.O. Box 5581 Löjtnantsgatan 21
114 85 Stockholm
114 85 Stockholm (SE)

   


(54) ELOVL2 CONSTRUCTS FOR GENE THERAPY